JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $19,523,000 | +11.4% | 427,121 | +9.4% | 0.01% | 0.0% |
| Q3 2017 | $17,519,000 | +53.2% | 390,518 | +2.1% | 0.01% | +66.7% |
| Q2 2017 | $11,438,000 | +50.7% | 382,631 | +11.8% | 0.00% | +50.0% |
| Q1 2017 | $7,592,000 | +42.9% | 342,163 | +21.4% | 0.00% | 0.0% |
| Q4 2016 | $5,312,000 | -36.3% | 281,837 | +1.4% | 0.00% | -33.3% |
| Q3 2016 | $8,341,000 | -19.2% | 277,940 | +3.5% | 0.00% | 0.0% |
| Q2 2016 | $10,323,000 | +82.2% | 268,553 | +80.6% | 0.00% | +50.0% |
| Q1 2016 | $5,665,000 | -8.4% | 148,724 | +5.7% | 0.00% | 0.0% |
| Q4 2015 | $6,185,000 | +29.8% | 140,663 | +20.1% | 0.00% | 0.0% |
| Q3 2015 | $4,765,000 | +69.5% | 117,104 | +122.1% | 0.00% | +100.0% |
| Q2 2015 | $2,812,000 | +14.4% | 52,733 | +30.1% | 0.00% | 0.0% |
| Q1 2015 | $2,459,000 | – | 40,539 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |